{"id":76771,"date":"2026-08-27T12:39:59","date_gmt":"2026-08-27T04:39:59","guid":{"rendered":"https:\/\/flcube.com\/?p=76771"},"modified":"2026-08-27T12:40:49","modified_gmt":"2026-08-27T04:40:49","slug":"junshi-biosciences-achieves-first-ever-semiannual-profitability-as-toripalimab-sales-surge-36","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76771","title":{"rendered":"Junshi Biosciences Achieves First\u2011Ever Semiannual Profitability as Toripalimab Sales Surge 36%"},"content":{"rendered":"\n

Shanghai Junshi Biosciences Co., Ltd.<\/strong> (HKG: 1877<\/a>, SHA: 688180<\/a>) announced its unaudited interim results for the six months ended June 30, 2026, reporting revenue of RMB 1,696.2 million<\/strong>, a 45.18% year\u2011on\u2011year increase<\/strong>, and swinging to a net profit of RMB 21.7 million<\/strong> versus a net loss of RMB 412.7 million in the same period last year \u2014 marking the company’s first\u2011ever semiannual profitability<\/strong> since its listing. Growth was primarily driven by expanded commercial sales of its core checkpoint inhibitor toripalimab (TUOYI)<\/strong> and a broad late\u2011stage pipeline advancing toward potential approvals.<\/p>\n\n\n\n

Financial Highlights \u2013 1H 2026<\/h2>\n\n\n\n
Metric<\/th>1H 2026<\/th>1H 2025<\/th>YoY Change<\/th><\/tr><\/thead>
Total Revenue<\/td>RMB 1,696.2 million<\/td>RMB 1,168.3 million*<\/td>+45.18%<\/td><\/tr>
Net Profit (attributable to shareholders)<\/td>RMB 21.7 million<\/td>Net loss of RMB 412.7 million<\/td>Swung to profit<\/td><\/tr>
Pharmaceutical Product Sales<\/td>RMB 1,407 million<\/td>\u2014<\/td>+33%<\/td><\/tr>
Toripalimab (TUOYI) Domestic Sales<\/td>~RMB 1,299 million<\/td>\u2014<\/td>~+36%<\/td><\/tr>
R&D Investment<\/td>RMB 644 million<\/td>\u2014<\/td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

*1H 2025 total revenue implied by the reported 45.18% year\u2011on\u2011year growth.<\/em><\/p>\n\n\n\n

Commercial Performance \u2013 Toripalimab (TUOYI)<\/h2>\n\n\n\n